Bladder drug delivery via catheter instillation is a widely used treatment for recurrence of superficial bladder cancer. Intravesical instillation of liposomal botulinum toxin has recently shown promise in the treatment of overactive bladder and interstitial cystitis/bladder pain syndrome, and studies of liposomal tacrolimus instillations show promise in the treatment of hemorrhagic cystitis. L...

INTRODUCTION The overactive bladder syndrome (OAB) is one of the most common and bothersome subsets of lower urinary tract symptoms (LUTS), affecting predominantly the aged population, with a worldwide distribution. This syndrome has not been completely understood, yet the aging process and the decreased blood flow to the bladder have been highlighted as closely related to this phenomenon. MA...

to evaluate overactive bladder (oab) with detrusor overactivity (doa) following oxybutynin or tolterodine treatment in recommended doses at a four-week course. a total of 100 iranian women 45 years or older with urgency that also showed idiopathic detrusor overactivity (ido) in the filling phase of their cystometry were included in the current study. in this double-blinded trial two parallel gr...

OBJECTIVES To analyze the relationship between symptom improvement and health-related quality of life in female overactive bladder patients treated with solifenacin. METHODS We carried out a prospective, multicenter, open-label study. Eligible patients were treatment-naive female patients with overactive bladder, with an urgency episode at least once a week. Symptoms were quantitatively asses...

Overactive bladder is a highly prevalent condition, affecting approximately 33 million adults in the United States. Despite the considerable impact this condition has on patients' quality of life, overactive bladder remains underrecognized and undertreated as a result of patient embarrassment and reluctance to seek medical help, as well as a lack of proactive questioning by physicians. The pres...

Serge P Marinkovic director of urology and female pelvic medicine and reconstructive surgery , Eric S Rovner professor of urology , Robert M Moldwin associate professor of clinical urology, director of the Interstitial Cystitis Center , Stuart L Stanton professor emeritus of urogynaecology , Lisa M Gillen independent researcher and writer , Christina MMarinkovic clinical director of nursing ser...

OBJECTIVES although efficacious, some patients do not respond optimally to overactive bladder (OAB) treatment. The objective of this study was to identify the reasons why some patients do not respond and to look for reasons for changes in treatment and patient satisfaction with the new treatment. MATERIALS AND METHODS epidemiological, cross-sectional, non-interventional study to determine the...

Nerve growth factor (NGF) has been suggested to play a role in bladder pain by mediating inflammation (12) and functional changes in sensory and sympathetic neurons innervating the urinary bladder (5). Clinically, diseases such as interstitial cystitis/painful bladder syndrome (IC/PBS) have been associated with elevated urinary levels of NGF (10) and the urothelium of individuals with IC/PBS pr...

Overactive bladder (OAB) is a syndrome involving urinary urgency with accompanying increased daytime urinary frequency and nocturia, with or without urgency urinary incontinence, in the absence of an urinary tract infection or other obvious pathology. The detailed OAB pathophysiology remains unclear. There is evidence that OAB pathogenesis also includes abnormal bladder paracrine activity, asso...